Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap giants kept the rally momentum alive.
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 3% year on year to $7.77 billion. On the other hand, the company’s full-year revenue guidance of $28.55 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $2.47 per share was 15.7% above analysts’ consensus estimates.
Wall Street slipped on Thursday as disappointing results from Meta and cautious tones from the Fed weighed on sentiment. But after the closing bell, Apple’s record-breaking numbers helped restore a bit of optimism.
Gilead Sciences Q3 2025 earnings beat EPS estimates with $2.47, but revenue outlook is cautious. HIV drug Biktarvy drives growth, while Veklury sales decline.
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) announced better-than-expected revenue in Q3 CY2025, with sales up 3% year on year to $7.77 billion. On the other hand, the company’s full-year revenue guidance of $28.55 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $2.47 per share was 15.7% above analysts’ consensus estimates.
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome Powell th
New York, NY – October 27, 2025 – A chorus of concern is growing louder across financial markets, with prominent voices like MarketWatch raising alarm bells over what they describe as an unprecedented overvaluation of the U.S. stock market. As major indices continue to notch new highs, analysts are pointing to
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the initiation of its pivotal Phase 2 DAYBreak clinical study. This critical advancement focuses on bexobrutideg (NX-5948), an investigational Bruton's tyrosine kinase (BTK) degrader,
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened interest is not merely an isolated phenomenon but rather a potent indicator of broader market movements, significantly impacting stock futures and the
In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market discussions about "dividend increases," the biotechnology firm has publicly stated it does not anticipate paying dividends in the immediate future. Instead, the company has
